{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:27:27Z","timestamp":1787113647410,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejca.2026.116899","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:19:53Z","timestamp":1782314393000},"page":"116899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Phase I\/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-7842","authenticated-orcid":false,"given":"Elena","family":"Garralda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5980-030X","authenticated-orcid":false,"given":"Patrick","family":"Sch\u00f6ffski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2207-6524","authenticated-orcid":false,"given":"Arjun","family":"Oberoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-3394","authenticated-orcid":false,"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Richly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0935-8298","authenticated-orcid":false,"given":"Rosa","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8387-4840","authenticated-orcid":false,"given":"Sandip Pravin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shonika","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Wang-L-akshman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8404-0581","authenticated-orcid":false,"given":"Jong Bong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia B.","family":"Hassounah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souvik","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2026.116899_bib1","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.3747\/co.27.5285","article-title":"Targeting T cell activation in immuno-oncology","volume":"27","author":"Saibil","year":"2020","journal-title":"Curr Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2026.116899_bib2","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1002\/j.1460-2075.1995.tb00035.x","article-title":"Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor","volume":"14","author":"Giri","year":"1995","journal-title":"EMBO J"},{"issue":"50","key":"10.1016\/j.ejca.2026.116899_bib3","doi-asserted-by":"crossref","first-page":"29862","DOI":"10.1074\/jbc.270.50.29862","article-title":"Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes","volume":"270","author":"Anderson","year":"1995","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.ejca.2026.116899_bib4","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4049\/jimmunol.180.4.2099","article-title":"Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+\/CD44high T cells and its antitumor action","volume":"180","author":"Dubois","year":"2008","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116899_bib5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/gt.2014.84","article-title":"Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells","volume":"22","author":"Bergamaschi","year":"2015","journal-title":"Gene Ther"},{"issue":"3","key":"10.1016\/j.ejca.2026.116899_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1158\/2326-6066.CIR-15-0009","article-title":"The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy","volume":"3","author":"Waldmann","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.ejca.2026.116899_bib7","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2003-12-4187","article-title":"Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance","volume":"105","author":"Kobayashi","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ejca.2026.116899_bib8","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1074\/jbc.M705725200","article-title":"Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity","volume":"283","author":"Bergamaschi","year":"2008","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.ejca.2026.116899_bib9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1182\/blood-2011-10-384362","article-title":"Circulating IL-15 exists as heterodimeric complex with soluble IL-15R\u03b1 in human and mouse serum","volume":"120","author":"Bergamaschi","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2026.116899_bib10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/cancers13040837","article-title":"Heterodimeric IL-15 in cancer immunotherapy","volume":"13","author":"Bergamaschi","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejca.2026.116899_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1886726","article-title":"Expand to shield: IL-15 and in situ lymphocytic proliferation","volume":"10","author":"Bindea","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2026.116899_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.imlet.2017.08.010","article-title":"The potential and promise of IL-15 in immuno-oncogenic therapies","volume":"190","author":"Robinson","year":"2017","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1016\/j.ejca.2026.116899_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000599","article-title":"Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-\u03b3, CXCL9 and CXCL10","volume":"8","author":"Bergamaschi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"24","key":"10.1016\/j.ejca.2026.116899_bib14","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1158\/1078-0432.CCR-10-1966","article-title":"Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model","volume":"16","author":"Yu","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2026.116899_bib15","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1007\/s00262-023-03453-z","article-title":"Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1\/PD-L1 blockade therapy","volume":"72","author":"Inoue","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"10.1016\/j.ejca.2026.116899_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007725","article-title":"First-in-human phase I\/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15R\u03b1, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors","volume":"11","author":"Leidner","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2026.116899_bib17","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial","volume":"16","author":"Lu","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116899_bib18","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"\"The use of confidence or fiducial limits illustrated in the case of the binomial\"","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"issue":"1","key":"10.1016\/j.ejca.2026.116899_bib19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4049\/jimmunol.1600019","article-title":"IL-15 trans-signaling with the superagonist RLI promotes effector\/memory CD8+ T cell responses and enhances antitumor activity of PD-1 antagonists","volume":"197","author":"Desbois","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2026.116899_bib20","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-20-0382","article-title":"Spartalizumab in metastatic, well\/poorly-differentiated neuroendocrine neoplasms","author":"Yao","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.116899_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/pst.1730","article-title":"Robust exchangeability designs for early phase clinical trials with multiple strata","volume":"15","author":"Neuenschwander","year":"2016","journal-title":"Pharm Stat"},{"issue":"11","key":"10.1016\/j.ejca.2026.116899_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003388","article-title":"Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors","volume":"9","author":"Conlon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116899_bib23","unstructured":"NCT02452268. Available on: Study Details | NCT02452268 | A Phase I\/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers | ClinicalTrials.gov."},{"key":"10.1016\/j.ejca.2026.116899_bib24","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","article-title":"IL-15 in the combination immunotherapy of cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2026.116899_bib25","unstructured":"NCT03388632. Available on: Study Details | NCT03388632 | Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers | ClinicalTrials.gov."},{"key":"10.1016\/j.ejca.2026.116899_bib26","unstructured":"NCT03905135. Available on: Study Details | NCT03905135 | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed\/Refractory Mature T-cell Malignancies | ClinicalTrials.gov."},{"key":"10.1016\/j.ejca.2026.116899_bib27","unstructured":"NCT02689453. Available on: Study Details | NCT02689453 | Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) | ClinicalTrials.gov."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:15:24Z","timestamp":1787112924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":27,"alternative-id":["S0959804926006805"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116899","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I\/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116899"}}